Business Description
Cytokinetics Inc
NAICS : 325412
SIC : 2834
ISIN : US23282W6057
Total Employee Number:
673Description
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.92 | |||||
Equity-to-Asset | -0.09 | |||||
Debt-to-Equity | -7.32 | |||||
Debt-to-EBITDA | -1.68 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -0.54 | |||||
Beneish M-Score | -0.53 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.4 | |||||
3-Year EBITDA Growth Rate | -14.8 | |||||
3-Year EPS without NRI Growth Rate | -11.2 | |||||
3-Year FCF Growth Rate | -8.8 | |||||
3-Year Book Growth Rate | -67.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 31 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 121.53 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.46 | |||||
9-Day RSI | 15.29 | |||||
14-Day RSI | 16.9 | |||||
3-1 Month Momentum % | 4.12 | |||||
6-1 Month Momentum % | 33.89 | |||||
12-1 Month Momentum % | 54.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.66 | |||||
Quick Ratio | 6.66 | |||||
Cash Ratio | 6.43 | |||||
Days Inventory | 11.97 | |||||
Days Sales Outstanding | 63.91 | |||||
Days Payable | 948.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9 | |||||
Shareholder Yield % | -4.42 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 87.97 | |||||
Operating Margin % | -1046.12 | |||||
Net Margin % | -1321.12 | |||||
EBITDA Margin % | -1118.12 | |||||
FCF Margin % | -848.9 | |||||
OCF Margin % | -811.9 | |||||
ROA % | -61.36 | |||||
ROIC % | -116.93 | |||||
3-Year ROIIC % | -73.24 | |||||
ROC (Joel Greenblatt) % | -503.46 | |||||
ROCE % | -59.83 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 137.81 | |||||
EV-to-EBIT | -12.75 | |||||
EV-to-Forward-EBIT | -15.08 | |||||
EV-to-EBITDA | -12.97 | |||||
EV-to-Forward-EBITDA | -15.08 | |||||
EV-to-Revenue | 145.01 | |||||
EV-to-Forward-Revenue | 22.02 | |||||
EV-to-FCF | -17.83 | |||||
Price-to-GF-Value | 0.32 | |||||
Price-to-Median-PS-Value | 4.26 | |||||
Earnings Yield (Greenblatt) % | -7.84 | |||||
FCF Yield % | -5.99 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cytokinetics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 58.073 | ||
| EPS (TTM) (€) | -6.191 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 62.1 | ||
| 14-Day RSI | 16.9 | ||
| 14-Day ATR (€) | 0.129688 | ||
| 20-Day SMA (€) | 63.832 | ||
| 12-1 Month Momentum % | 54.53 | ||
| 52-Week Range (€) | 42.8 - 76.12 | ||
| Shares Outstanding (Mil) | 139.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cytokinetics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cytokinetics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 162 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-24 16:30 | In 161 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 16:00 | In 161 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 50 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 16:00 | In 50 days | ||
| Bernstein 3rd Annual Healthcare Forum | 2026-09-23 08:50 | In 7 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-14 07:45 | 62.98 (+0.00%) | ||
| Guidance call for 2026 | 2026-09-10 11:30 | 62.98 (+0.00%) | ||
| Guidance call for 2026 | 2026-09-09 15:00 | 62.98 (+0.00%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 71.28 (+0.00%) |
Show
Entries
Cytokinetics Inc Frequently Asked Questions
What is Cytokinetics Inc(MIL:1CYTK)'s stock price today?
The current price of MIL:1CYTK is €62.98. The 52 week high of MIL:1CYTK is €76.12 and 52 week low is €42.80.
When is next earnings date of Cytokinetics Inc(MIL:1CYTK)?
The next earnings date of Cytokinetics Inc(MIL:1CYTK) is 2026-11-05 Est..
Does Cytokinetics Inc(MIL:1CYTK) pay dividends? If so, how much?
Cytokinetics Inc(MIL:1CYTK) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers